Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer’s disease: Multimodal Preventive Trial for Alzheimer’s Disease (MIND-ADmini)
-
Published:2024-07-03
Issue:1
Volume:16
Page:
-
ISSN:1758-9193
-
Container-title:Alzheimer's Research & Therapy
-
language:en
-
Short-container-title:Alz Res Therapy
Author:
Levak Nicholas,Lehtisalo Jenni,Thunborg Charlotta,Westman Eric,Andersen Pia,Andrieu Sandrine,Broersen Laus M.,Coley Nicola,Hartmann Tobias,Irving Gerd Faxén,Mangialasche Francesca,Ngandu Tiia,Pantel Johannes,Rosenberg Anna,Sindi Shireen,Soininen Hilkka,Solomon Alina,Wang Rui,Kivipelto Miia
Abstract
Abstract
Background
Multimodal lifestyle interventions can benefit overall health, including cognition, in populations at-risk for dementia. However, little is known about the effect of lifestyle interventions in patients with prodromal Alzheimer’s disease (AD). Even less is known about dietary intake and adherence to dietary recommendations within this population making it difficult to design tailored interventions for them.
Method
A 6-month MIND-ADmini pilot randomized controlled trial (RCT) was conducted among 93 participants with prodromal AD in Sweden, Finland, Germany, and France. Three arms were included in the RCT: 1) multimodal lifestyle intervention (nutritional guidance, exercise, cognitive training, vascular/metabolic risk management, and social stimulation); 2) multimodal lifestyle intervention + medical food product; and 3) regular health advice (control group). Adherence to dietary advice was assessed with a brief food intake questionnaire by using the Healthy Diet Index (HDI) and Mediterranean Diet Adherence Screener (MEDAS). The intake of macro- and micronutrients were analyzed on a subsample using 3-day food records.
Results
The dietary quality in the intervention groups, pooled together, improved compared to that of the control group at the end of the study, as measured with by HDI (p = 0.026) and MEDAS (p = 0.008). The lifestyle-only group improved significantly more in MEDAS (p = 0.046) and almost significantly in HDI (p = 0.052) compared to the control group, while the lifestyle + medical food group improved in both HDI (p = 0.042) and MEDAS (p = 0.007) during the study. There were no changes in macro- or micronutrient intake for the intervention groups at follow-up; however, the intakes in the control group declined in several vitamins and minerals when adjusted for energy intake.
Conclusion
These results suggest that dietary intervention as part of multimodal lifestyle interventions is feasible and results in improved dietary quality in a population with prodromal AD. Nutrient intakes remained unchanged in the intervention groups while the control group showed a decreasing nutrient density.
Trial registration
ClinicalTrials.gov NCT03249688, 2017–07-08.
Funder
Alzheimerfonden
Demensfonden
EU Joint Programme – Neurodegenerative Disease Research
ZonMw
Hjärnfonden
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
European Research Council
Center for Innovative Medicine
Knut och Alice Wallenbergs Stiftelse
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Karolinska Institutet
NordForsk
Karolinska Institute
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e25.
2. Alzheimer's Disease International. World Alzheimer Report 2015 The Global Impact of Dementia An analysis of prevalence, incidence, cost and trends London: Published by Alzheimer’s Disease International (ADI); 2015
3. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2022;9(2):197–210.
4. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.
5. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.